Skip to content

Coated Metal Ureteral Stent in the Treatment of Radiation Induced Ureteral Stricture

Efficacy and Safety of Coated Metal Ureteral Stent in the Treatment of Radiation Induced Ureteral Stricture, A Prospective, Mutlcenter and Controlled Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04441320
Enrollment
100
Registered
2020-06-22
Start date
2021-01-01
Completion date
2024-12-31
Last updated
2022-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hydronephrosis, Radiation Exposure, Ureteral Stricture

Keywords

radiation induced ureteral stricture, coated metal ureteral stent, safety, efficacy

Brief summary

A prospective, multicenter and controlled study to observe the efficacy and safety of coated metal ureteral stent in the treatment of radiation induced ureteral stricture.

Interventions

DEVICECoated metal ureteral stent(CMUS)

Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.

DEVICEDouble-J stent(DJS)

Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.

Sponsors

Peking University People's Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

1. Clinical diagnosis of ureteral stricture and hydronephrosis. 2. Previous history of radiation therapy. 3. Must be able to tolerate surgery.

Exclusion criteria

1. Combine with hypertonic neurogenic bladder (except for patients with long-term indwelling catheter). 2. Colon resection surgery patients.

Design outcomes

Primary

MeasureTime frameDescription
Patency rateUp to 36 monthsNumber of patients evaluated with hydronephrosis
Indwelling timeUp to 36 monthsNumber of months of the implant in the ureter
Device related serious adverse eventsUp to 36 monthsNumber of device related serious adverse events

Countries

China

Contacts

Primary ContactMingrui Wang
wangmingrui1995@pku.edu.cn19801286883

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026